Navigation Links
Palatin Technologies, Inc. Announces Dosing of Subcutaneous Bremelanotide Trial in Men
Date:2/9/2010

CRANBURY, N.J., Feb. 9 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) today announced the completion of first cohort dosing in a placebo-controlled, multiple dose study of bremelanotide, its experimental treatment for sexual dysfunction.  The primary endpoint in this double-blind safety study is evaluation of blood pressure effects of subcutaneous bremelanotide in men between 45 and 65 years old.  The study will also evaluate consistency of plasma exposure of bremelanotide given as repeated subcutaneous injections.

Palatin anticipates completing the study in the current calendar quarter, with data analysis completed in the next calendar quarter.

"The current study is designed to validate our hypothesis that increases in blood pressure and gastrointestinal events seen with intranasally administered bremelanotide were primarily related to high intranasal absorption in a subset of patients. The results from this study in the male demographic we are targeting for commercialization, combined with results from our study reported last August, are intended to further address concerns raised by the Food and Drug Administration," said Trevor Hallam, Ph.D., Executive Vice President of Research and Development of Palatin.

Data from this study will be submitted to the Food and Drug Administration.  Palatin intends to initiate a Phase 2, at-home, study of subcutaneous bremelanotide in men with erectile dysfunction who are not responsive to therapies with drugs such as Viagra®, a brand of sildenafil citrate, in the second half of this calendar year.  The Phase 2 bremelanotide erectile dysfunction program is designed to provide the data required to initiate Phase 3 registrati
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Palatin Technologies to Present at 8th Annual BIO Investor Forum
2. Palatin Technologies Presents PL-3994 Clinical Trial Results at the 12th Annual Scientific Meeting of the Heart Failure Association of America
3. Palatin Technologies Initiates Phase 2 Hypertension Clinical Study With PL-3994
4. Palatin Technologies, Inc. Reports Initiation of Human Trials for the Treatment of Congestive Heart Failure
5. King Pharmaceuticals and Palatin Technologies Delay Immediate Plans for Phase 3 Clinical Program With Bremelanotide for Erectile Dysfunction
6. Wound Management Technologies, Inc. Engages Miller Tabak, A National Investment Banking Firm Specializing in the Healthcare Market Space
7. Wound Management Technologies, Inc. Targets Multi-Billion Dollar Biomaterials Market; Releases Update on Resorbable Orthopedics
8. AVAX Technologies, Inc. Closes Bridge Financing
9. Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging
10. Wound Management Technologies, Inc. Signs Agreement with Major Sales Representative Organization for Increased Marketing of CellerateRx(R); Third Quarter Sales Up
11. Instacare Moves to Secure Patents for Its Newest Technologies, Announces Parallel Strategies for Its Revolutionary MD@Hand Cell-Centric Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... 23, 2015  Northwest Biotherapeutics, Inc. (NASDAQ: NWBO )("NW ... for operable and inoperable solid tumor cancers, announced today that ... th Annual Phacilitate Immunotherapy Forum in Washington ... will take place on January 26 at 10:30 a.m. EST ...
(Date:1/23/2015)... a third of reproductive-aged women enrolled in Medicaid, and more ... prescription for an opioid pain medication each year during 2008-2012, ... Weekly Report (MMWR). Opioids are typically prescribed ... They are also found in some prescription cough medications. The ...
(Date:1/23/2015)... Feffer LLP ( www.hfesq.com ) is investigating potential claims ... or the "Company") (NASDAQ: ADXS ), concerning ... shareholders. On January 21, 2015, an article ... had misrepresented the clinical data for its ADXS-HPV drug ...
Breaking Medicine Technology:NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 2NW Bio To Present At The 7th Annual Phacilitate Immunotherapy Forum 3Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3Harwood Feffer LLP Announces Investigation of Advaxis, Inc. 2
... announces that a new market research report is available ... http://www.reportlinker.com/p0357031/Regenerative-Medicine-Markets.html Regenerative ... human tissue by using laboratory-grown or therapeutically-induced human tissue ... the ability to repair or replace damaged human tissue ...
... YORK, Dec. 29, 2010 Reportlinker.com announces that ... its catalogue: 2010-2015 In-depth Research ... http://www.reportlinker.com/p0356862/2010-2015-In-depth-Research-Report-on-China-Sodium-Fluoride-Industry.html Report ... State Statistical Bureau, General Administration of Custom, Ministry ...
Cached Medicine Technology:Reportlinker Adds Regenerative Medicine Markets 2Reportlinker Adds 2010-2015 In-depth Research Report on China Sodium Fluoride Industry 2
(Date:1/22/2015)... The Incredible Bulk is a revolutionary method put ... muscle by up to 30lbs in less than 12 weeks ... Stan Stevenson, prompting an investigative review. , “Our Incredible ... diet formula that allows the body to pack on a ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 Blue Cross and ... Minnesotans who exemplify what it means to “Live Fearless.” ... for people to share their stories about how they or ... simply inspired others by living in the moment. By telling ...
(Date:1/22/2015)... New York (PRWEB) January 22, 2015 The ... ) in the U.S. District Court, Southern District of West ... Bard, Inc. in that proceeding’s first bellwether trial. In an ... for a new trial after finding that C.R. Bard had ...
(Date:1/22/2015)... A new white paper by The Beryl ... the long-term care environment as well as provides recommendations ... paper, “The Power of Person-Centeredness in Long-Term Care: A ... the patient, resident and family experience in long-term care ...
(Date:1/22/2015)... Autocarinsurancebest.com has released a new blog post ... insurance policy . , Auto insurance quotes help many ... no longer necessary to call an agent or visit an ... on a single website: http://autocarinsurancebest.com/ . , Every business ...
Breaking Medicine News(10 mins):Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Court Upholds $2 Million Vaginal Mesh Lawsuit Verdict Levied Against C.R. Bard in First Federal Bellwether Trial, Bernstein Liebhard LLP Reports 4Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Commercial Auto Insurance Provides Several Important Features! 2
... cut bleeding time in half, but use in humans is ... Hoping to improve on nature, researchers have built and tested ... used in trauma or other cases where blood just won,t ... material that is used in degradable stitches, which dissolve in ...
... determining factor for use, expert says, , WEDNESDAY, Dec. 16 ... less likely to die when they receive an implantable cardioverter ... people, ages 65 to 85, who were eligible for the ... the heart,s pumping ability) of 35 percent or less. , ...
... Dec. 16 Medical travel facilitator Companion Global Healthcare ... into its network of international hospitals that treat American ... U.S. facilities. , The announcement means Companion Global Healthcare ... its individual clients and employer group members who seek ...
... FRANCISCO, Dec. 16 Quantros, Inc., a leading provider ... for the healthcare industry, announces the creation of a ... industry veteran Michael Tulloch, MBA, as Director of IT ... Marlborough, MA office. , "The expansion into IT services ...
... happens when the families of sick and dying hospitalized children ... How do pediatricians respond to such personal requests? While increasing ... patients and families cope with serious illness, a new study ... who raise the issue of prayer, not the doctors themselves. ...
... Dec. 16 Tyco International Ltd. (NYSE: TYC ... election to the Tyco Board of Directors at the company,s ... 55, is Senior Vice President of the Global Technology Services ... has worldwide responsibility for IBM,s Global Services business operations consisting ...
Cached Medicine News:Health News:Synthetic Platelets Put the Brakes on Blood Loss 2Health News:Synthetic Platelets Put the Brakes on Blood Loss 3Health News:Implanted Defibrillator Might Extend Life 2Health News:Hospitals in Puerto Rico Join Companion Global Healthcare's Network 2Health News:Safety and Quality Software Developer Quantros, Inc. Launches Healthcare IT Consulting Division 2Health News:Prayer on the hospital floor 2Health News:Tyco International Files Preliminary Proxy Proposing Election of New Director 2
Midstream Catch Kits...
... is a portable, noninvasive ultrasound instrument that ... to use, and quickly provides accurate results. ... use the BladderScan® to obtain a precise ... BladderScan® supplies the information that caregivers need ...
... Mobile BladderScan® BVI 6400 calculates bladder ... technology. V-MODE® ultrasound is accurate, fast, ... the BladderScan® measures ultrasonic reflections within ... creates a 3-dimensional image of the ...
... The Titan™ Inflatable Penile Prosthesis ... designed to be surgically implanted ... management of erectile dysfunction (also ... provides the patient with voluntary ...
Medicine Products: